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Abstract: Although it was suggested that heparanase (HPSE) may affect implantation and pregnancy, so far there 
have been no wide-ranging studies on the expression of and possible disturbances in the interactions between HPSE, 
heparan sulfate (HS) and related growth factors, such as heparin-binding EGF-like growth factor (HB-EGF). The aim 
of this study was to evaluate whether the expression profile of both HPSE and HB-EGF can be associated with impa-
ired reproduction in the endometrial implantation window, in the non-conception cycle. The study group consisted of 
32 women with two or more unexplained, consecutive miscarriages, and 61 idiopathic infertility patients, while the con-
trol comprised of 22 women with normal reproductive potential. We compared the expression of HB-EGF and HPSE 
at the transcript (qPCR) and protein (Western Blot) levels in eutopic endometrium. Also assessed were correlations 
between both factors in the studied groups. In women with consecutive miscarriages we observed lower HPSE relative 
transcript (p = 0.003) and lower protein (p = 0.002) level compared with the control group. Level of the HB-EGF 
protein was decreased (p = 0.017). HPSE mRNA level was higher in idiopathic infertility (p = 0.003) compared with 
women with miscarriages. We found statistically significant correlations in both transcript and protein levels in all groups 
(p < 0.05). Our results allow the assumption of the existence of a process by which, in normal human endometrium, 
HB-EGF expression coincides with the synthesis of HPSE. As a result, the HB-EGF molecule can bind to the HS on 
the cell surface, enhancing its affinity to the receptor. Then, the release of growth factors associated with HS oligomers 
occurs that is catalyzed by HPSE. We suggest that one of the causes of unexplained miscarriages may result from the 
impaired expression of HPSE and HB-EGF. (Folia Histochemica et Cytobiologica 2013, Vol. 51, No. 2, 127–134)
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Introduction
Implantation of the embryo is a key moment for the 
further development of the pregnancy. For this to hap-
pen, both the embryo and the mother must be properly 
prepared. The ability of the endometrium to accept the 
embryo occurs 7–9 days after ovulation and is manifested 
by a series of morphological and biochemical features, 
which are referred to collectively as endometrial recep-
tivity [1]. Despite the many potential factors responsible 
for the success of the implantation, it still remains the 
period of pregnancy that has the highest risk of failure. 
Only 50–60% of the embryos develop past 20 weeks 
of gestation. It is estimated that 75% of blastocysts are 
not implanted in the endometrium, remaining clinically 
unrecognized pregnancies [2–4].
The study of implantation in animal models, in 
relation to humans, may be subject to erroneous 
conclusions. This is due to the specific biochemical 
and physiological differences in implantation that are 
specific for mammalian species. It is a fact that the 
common and necessary step for implantation is the 
direct contact of the blastocyst with the endothelial 
lining of the uterus — the receptive endometrium [5].
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From a clinical perspective it is important to find 
factors that can be used to determine the maturity of 
endometrial and/or the chances of successful pregnan-
cy in patients with impaired reproduction. Among 
the candidates for biochemical markers are adhesion 
molecules: aVb3 integrin, E-cadherin and glycocalyx 
glycosaminoglycans [6–9]. It should also be noted that 
the embryo is an entity allogenic to the mother, and 
the success of implantation, and in consequence pregnan-
cy, depends on the immune status of the endometrial 
environment. Therefore, many researchers believe that 
the cause of failure of pregnancies lies in the mother’s 
immunological profile, characterized by cytokines and 
certain subpopulations of lymphocytes [10].
Implantation and trophoblast invasion is also 
associated with changes in the tissue structure. The 
building blocks of the extracellular matrix (ECM), 
together with the ECM-degrading enzymes, are 
responsible for this process. The ECM not only ma-
intains the tissue structure, but is also responsible 
for its receptivity, remodeling, angiogenesis and the 
creation of connections between the trophoblast and 
decidua [11].
An important component of ECM is heparan 
sulfate (HS). Its presence has been demonstrated in 
the endometrium, the decidua and the trophoblast 
invasion area [12]. HS not only acts as an integrating 
molecule by binding tissues and cells. It is also a bin-
ding and release site for angiogenic growth factors 
such as heparin-binding EGF-like growth factor 
(HB-EGF), vascular epithelial growth factor (VEGF) 
and fibroblast growth factor family (FGF’s), as well 
as bone morphogenetic proteins (BMP’s). Binding 
of these factors with HS as a co-receptor not only 
increases their concentration, but also modulates 
their effects on target cells [13, 14]. On the other 
hand, ECM stimulates angiogenesis and growth of 
the trophoblast by releasing factor-HS complex [15].
Heparanase or endo-b-D-glucuronidase (HPSE) 
is responsible for HS degradation, cell migration and 
release of heparan sulfate binding agents, which divi-
des the sugar chains at specific sites, generating short 
oligosaccharides, consisting of 10–20 sugar residues 
[16]. HPSE, a factor influencing vascularization and 
growth, has been extensively studied in the process of 
carcinogenesis. HPSE is expressed in human tumors. 
Its over-expression confers an accelerated growth 
and invasive phenotype in experimental animals. In 
contrast, HPSE gene silencing is associated with a 
marked inhibition of tumor progression. Heparanase 
upregulation correlates with increased tumor vascula-
rity and poor postoperative survival of cancer patients 
[17]. Oncological studies demonstrated not only the 
enzymatic, but also non-enzymatic, angiogenic acti-
vity of HPSE [18]. Additionally, it has to been noted 
that the reduction in the expression of HPSE in vitro 
impairs, in a non-enzymatic way, angiogenesis and 
hemostasis by reducing the expression of VEGF and 
tissue factor (TF) [19].
It is not known whether an analogous situation 
occurs in the endometrium. There has been relati-
vely little research on the role of HPSE expression 
and the processes related to endometrial receptivity 
and implantation. In mammals, including primates 
and humans, expression of HPSE has been found in 
endometrium and placenta, whereas a murine mo-
del has demonstrated its key role in the process of 
implantation [20–26].
Studies on mouse blastocyst implantation have 
shown that the synthesis of HB-EGF is closely asso-
ciated with the implantation site. In a mouse endome-
trium HB-EGF is produced in the form of a protein 
associated with endometrial epithelium that binds to 
HS present on the surface of the blastocyst, and, as 
demonstrated in vitro, endometrial HB-EGF acts as 
the blastocyst growth factor through the receptors 
for epidermal growth factors (EGF) — HER1 and 
HER4 [27, 28].
Although it has been suggested that HPSE affects 
implantation and pregnancy, so far there have not been 
any wide-ranging studies on the expression of and pos-
sible disturbances in the interactions between HPSE, 
HS and related growth factors (such as HB-EGF) in 
implantation in women with impaired reproduction.
In this investigation we tried to assess the expres-
sion of both HPSE and HB-EGF. We aimed to answer 
the question as to whether the expression profile of 
both markers may be associated with impaired repro-
duction in the endometrial implantation window, in 
the non-conception cycle. 
Material and methods
Patients and controls. The study, which was approved by 
Karol Marcinkowski Medical University bioethical com-
mittee, included 115 reproductive-age women. The study 
group consisted of 32 women with two or more unexplained, 
consecutive miscarriages, 61 idiopathic infertility patients 
and the control group comprised of 22 women with normal 
reproductive potential. The women in the miscarriage group 
have had at least two consecutive unexplained miscarriages 
in the first trimester of pregnancy. This group included 
20 women with diagnosed recurrent miscarriage (e.g. 3 con-
secutive miscarriages). The mean duration of infertility in 
idiopathic infertility patients was 3 years (range: 1–5 years). 
The control group consisted of women that had at least 
one child, regular menses, and were without anatomical or 
functional changes within the endometrium. Those patients 
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were asked to donate their endometrium for the investiga-
tion. The study protocol was approved by the local ethical 
committee, and the patients signed an informed consent 
form. No patients in the study or control group had taken 
any hormonal preparations for at least three months prior to 
the study. The exclusion criteria were: current use of hormo-
nal contraception, any serious diseases. The age of women, 
number of miscarriages and parity are presented in Table 1. 
Sample collection. In each woman endometrium samples 
was scraped from uterine wall. A pipelle or hysteroscopic 
biopsy was used to acquire samples during the implantation 
window, which occurred 7–9 days after ultrasound confirmed 
ovulation. Part of the each sample was taken for histological 
assessment, according to the Noyes and Hertig criteria [29]. 
The reminder of the endometrial sample for qPCR and 
Western blot was placed overnight in Allprotect Tissue 
Reagent solution (Qiagen GmbH, Hilden, Germany) and 
next frozen in liquid nitrogen until extraction.
RNA isolation and protein extraction. Both fractions were 
conducted with the use of an AllPrep DNA/RNA/Protein 
Mini Kit (Qiagen). For the total RNA isolation we used, 
due to the manufacturer recommendation an additional 
RNase-Free DNase Set (Qiagen) to eliminate the risk of 
DNA contamination. 
Reverse transcription and qPCR. The quantity at OD 260 
nm and purity at OD 260/280 nm of the total RNA samples 
was checked spectrophotometrically with a NanoDrop 
ND1000 (Thermo Scientific, USA), after RNA isolation. 
To acquire cDNA, the 1 μg RNA was treated with Quanti-
Tect Reverse Transcription (Qiagen). Up to 30 ng resulting 
cDNA was used as a matrix for qPCR. 
The expression of the studied transcripts was established 
according to a housekeeping gene, namely the human large 
ribosomal protein (RPLP0). Specific primers for HPSE and 
HB-EGF in qPCR technique were created with Primer3 so-
ftware [30] based on an mRNA sequence from the NCBI Gene 
database [31]. Primers for RPLP0 were designed on the basis 
of the RTPrimerDB [32]. The specificity of the constructed 
primer was checked against the BLAST database [33]. The 
specificity and length of these products was also confirmed on 
agarose. The following primers were used: for HPSE forward: 
5’-ATCAATGGGTCGCAGTTAGG — 3’ and reverse: 5’ — 
AGGCTGACCATCAGGAC — 3’, for HB-EGF — forward: 
5’ — TGAGGTGGGTGGGATTATACA — 3’ and reverse: 
5’TTGGAGCTGACTGTTCTTGGT3’, and for RPLP0 — 
forward: 5’ — GGCGACCTGGAAGTCCAACT — 3’ and 
reverse 5’ — CCATCAGCACCACAGCCTTC — 3’.
All reactions were conducted using a DyNAmo HS 
SYBR Green qPCR Kit (Finnzymes, Finland) and a Rotor-
Gene 3000 thermocycler (Corbett Research, Australia). The 
specificity of the achieved reaction products was assessed in 
2% agarose gel and a second derivative of the melting curve 
for the PCR reaction. The thermal profile was based on the 
manufacturer’s instructions regarding the specific annealing 
temperature of the primers. To establish the levels of the 
given transcripts in the studied samples, we constructed 
standard curves generated by the Ct (the value where the 
amplification curve crosses the threshold line) with six 
subsequent ten-fold dilutions of linear DNA, which was the 
PCR product of a given set of primers. For each sample, 
duplicated qPCR was processed in the presence of positive 
controls and no template control. The HPSE, HB-EGF and 
RPL0 mRNA levels were expressed as the ratio of studied 
and reference cDNA amount.
Western blot analysis. Previously obtained sample extracts, 
containing 30 μg of protein samples, were separated by elec-
trophoresis in a 4–12% SDS-polyacrylamide gel (Bis-Tris 
NuPAGE, Invitrogen, USA). The separated proteins were 
transferred to a PVDF membrane and blocked with TBST 
(TBS plus 0.1% Tween-20) containing 4% BSA. Immuno-
detection was processed with the use of rabbit polyclonal 
antibody anti-HPSE (H-80, 200 μg/mL) and rabbit polyclo-
nal antibody anti-HB–EGF (H-88; 200 μg/mL, Santa Cruz 
Biotechnology, Dallas, TX, USA) at 1:200 concentrations. 
For ACTB detection, rabbit polyclonal anti-ACTB antibody 
was used at a 1:400 concentration (N-21; 100 μg/mL, Santa 
Cruz). Goat anti-rabbit, conjugated with Alexa Fluor 663 
(Invitrogen, USA), was used as the secondary antibody. 
Bands were revealed using a Fuji FLA5100 Fluorescent 
Image Analyser (FujiFilm, Japan) scanner. The quantities 
Table 1. Clinical characterization of the studied groups.
n Age Number of mi-
scarriages 
Infertility dura-
tion (years)
Parity
Median Span Median Span Median Span Median Span
Miscarriage group 32 32 23–41 3 2–5 NA 0
Two consecutive, unexplained miscarriages 12 33 27–41 2 2
Clinically diagnosed recurrent miscarriage 20 32 23–40 3 3–5
Idiopathic Infertility 61 32 25–40 NA 3 1–5 0
Control group 22 39 19–43 NA NA 1 1–3
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of Western blot-detected HPSE and HB-EGF and ACTB 
proteins were determined based on the fluorometry. The 
band fluorometry readings were normalized to the ACTB 
loading control to calculate the studied protein to ACTB 
fluorescent signal ratio. 
Statistical analysis. For statistical analysis, SigmaStat3.5 
software was used (Systat Software, Inc., USA). The analysis 
of the results was based on Kruskal–Wallis one-way ANOVA 
on Ranks with Multiple Comparisons versus Control Group 
(Dunn’s Method) and the Spearman Rank Correlation Test; 
p < 0.05 was considered statistically significant.
Results
We used qPCR and Western blot analysis to evaluate 
HPSE and HB-EGF transcript and protein levels 
in the endometrium samples of women with two or 
more unexplained miscarriages, idiopathic infertility 
patients and the controls. In women with consecuti-
ve miscarriages, we observed lower HPSE relative 
transcript level (p = 0.003) and lower protein level 
(p = 0.002) compared to controls. The level of HB-
-EGF proteins was lower (p = 0.017) but the level of 
the HB-EGF transcript, despite the fact that it was 
lower, was not statistically different when compared 
with the controls (trend p < 0.164).
Expression of the studied genes, despite being 
lower, was not significantly different in women with 
idiopathic infertility compared with the controls. 
Also, we have not observed any statistically signifi-
cant differences between women with miscarriages 
and infertile women, with the exception of the HPSE 
mRNA level, which was higher in idiopathic infertility 
(p = 0.003) (Table 2).
We also compared correlations between HPSE 
and HB-EGF levels in all the studied groups. We 
found statistically significant correlations both in 
transcript and protein levels in all groups (p < 0.05) 
(Figure 1).
Discussion
HPSE in the endometrium, in both mice and 
humans, changes the glycocalyx structure, and 
removes HS facilitating mutual contact between 
the embryo and the decidua. However, in the pro-
cess of implantation, it seems more appropriate 
to view the HPSE as an adhesive agent and/or 
a protein transcription factor [34]. In turn, an 
in vivo mouse model, and later also in primates, 
a multiple increase in HPSE enzyme activity was 
demonstrated during pregnancy. This phenomenon 
was not accompanied by increased expression of 
HPSE in relation to the expression of this protein 
in the endometrium during the implantation win-
dow. A similar phenomenon was also observed in 
the human decasualization of the endometrium in 
vitro [35, 36]. These observations, regarding the 
level of the HPSE protein and its activity in the 
endometrium and decidua in mammals, indicate 
a biochemical mechanism that switches the function 
of HPSE from an adhesion molecule and/or signa-
ling functional hydrolase. During the implantation 
window HPSE would assist embryo implantation, 
and during pregnancy HPSE acts as an angioge-
nesis-stimulating factor, and mostly as a catalyst 
in the ECM changes. One of the mechanisms that 
controls the activity of HPSE may be a change in 
pH. It has been shown that the catalytic activity 
Table 2. Relative transcript and protein level of HPSE or HB – EGF in endometrium from women with two or more 
consecutive miscarriages, idiopathic infertility and the control group
Gene Controls  
n=22
Two or more consecutive miscar-
riages n = 32
Idiopathic infertility n=61
Median  
(span)
Mean  
(± SD)
Median  
(span)
Mean  
(± SD)
Median  
(span)
Mean  
(± SD)
HPSE Transcripta 0.056  
(2.95E-3–0.153)
0.068 
(±0.007)
0.011 
(5.17E-4–0,312)*†
0.045  
(±0.015)
0.04  
(4.87E-4–0.797)†
0.107  
(± 0.022)
Proteinb 0.565  
(0.006–1.173)
0.525 
(±0.421)
0.01 
(0.005–0.821)*
0.077  
(±0.211)
0.017 
 (0.005–1.091)
0.296  
(± 0.395)
HB
-EGF
Transcripta 0.0113  
(1.5E-3–0.0484)
0.014 
(±0.012)
0.009  
(1.0E-3–0.124)
0.016 
(±0.021)
0.007  
(5.24E-4–0.115)
0.011  
(± 0.016)
Proteinb 0.641  
(0.052–3.6962)
1.028 
(±0.223)
0.015  
(0.01–1188)**
0.4 
(±0.407)
0.404  
(0.010–1.367)
0.487  
(± 0.411)
 aThe amount of cDNA corresponding to HPSG and HB-EGF transcripts, were normalized to RPL0 housekeeping gene transcript; bThe amount 
of Western blot-detected proteins was presented as the HPSE or HB-EGF to ACTB protein band fluorescent signal ratio. P values for studied 
groups vs. controls were assessed by ANOVA on Ranks with Multiple Comparisons versus Control Group (Dunn’s Method). *p < 0.005;  
**p < 0.05; †p < 0.005
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Figure 1. HPSE and HB-EGF correlation, assessed by Spearman Rank Order Correlation. The correlation coefficients 
value and p-value were depicted in upper-right corners. Dashed lines define the 95% confidence interval
of HPSE reaches a maximum at pH 5.0, while the 
pH during the menstrual cycle in the uterine cavi-
ty varies between 6.6 and 7.6. This pH favors the 
adhesive properties of HPSE, even in the form of 
a proenzyme that is catalytically inactive [37–39].
In our study, the expression of HPSE in women 
with two or more abortions was significantly lower 
compared with the control group. Also, it the same 
group, the transcript level of HPSE was lower com-
pared with infertile women; whereas HPSE protein 
levels in infertile women did not differ compared 
with the control group . Taking this into account, 
one can assume that in the decidua in the early 
stages of pregnancy HPSE — by its proangiogenic 
activity – is responsible for the maintenance of 
pregnancy and trophoblast invasion. On the other 
hand, it is responsible, to a lesser extent, for the 
direct binding of the embryo to the endometrium, 
thus initiating the implantation. 
Nadir et al. [40], showed that in placental biopsies 
derived from women with recurrent miscarriage and 
thrombophilia expression level of HPSE was higher 
in relation to the results obtained from placentas, 
from women without a negative obstetric history. 
However, in histological material derived from wo-
men with thrombophilia and recurrent fetal loss and 
also in the controls stronger HPSE expression was 
observed in placental fragments of fetal origin com-
pared to fragments of maternal origin [40]. Perhaps 
the cause of early pregnancy loss could be traced back 
to the imbalanced expression of HPSE and its control 
mechanisms and its activation in the placenta. The 
same authors also pointed to the thrombotic activity 
of HPSE [41].
132 P. Wirstlein et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2013
10.5603/FHC.2013.0020
www.fhc.viamedica.pl
We both evaluated the transcript as well as the 
level of the HB-EGF protein. In women with two or 
more consecutive pregnancy losses we have observed 
lower, but statistically not significant levels of the HB
-EGF transcript confirming our earlier studies [42]. 
Thus, the results of the expression of both HB-EGF 
and HPSE seem to suggest an important role of these 
proteins in the development of the placenta.
In contrast to the mouse, HB-EGF in human 
endometrium is also synthesized in the stroma (at 
the mRNA level, throughout the whole cycle), the 
decidua and the chorion [43]. The correlation of in-
creased synthesis of HB-EGF and EGFR receptors in 
the stroma suggests that in the human endometrium 
HB-EGF has a more complex role than that found 
in mice. It is postulated that in the human endome-
trium HB-EGF acts as a factor responsible for the 
maturation of the endometrium and decasualization, 
via possible regulation of apoptosis in stromal cells. 
In addition, HB-EGF has been shown to have incre-
ased affinity for the EGFR when it is associated with 
HS [44]. HB-EGF stimulates the expression of those 
factors limiting the activation of the complement. The 
ability of HB-EGF to stimulate tumor invasion was 
demonstrated by many authors [45–48]. Similarly, as 
in the case of HPSE, it can be assumed that HB-EGF 
promotes not only implantation, but also plays an 
important role in trophoblast invasion. These findings 
should explain the beneficial effects of low molecu-
lar weight heparin (LMWH) on the maintenance of 
pregnancy. We can assume that LMWH works as an 
antithrombotic agent, and thus antagonizes the afore-
mentioned thrombotic action of HPSE, as described 
by Nadir et al. [40]. However, the protective effect 
of LMWH during pregnancy stands in opposition to 
the observed its anti-neoplastic effect [49]. Moreover, 
LMWH has an antiapoptotic effect and stimulates the 
expression of HB-EGF in decidual cells in vitro [50].
It has been independently shown that the expres-
sion of both HPSE and HB-EGF in the endometrium 
is stimulated by sex hormones [51, 52]. Both factors 
are important for implantation and their roles seem 
to be complementary. 
We found positive correlation between expression 
of the HPSE and HB-EGF in the control, and both 
studied groups. There was a strong correlation of 
the transcripts of HPSE and HB-EGF in the group 
of women with primary infertility. On the one hand, 
this is probably the effect of group size. It is almost 
three times greater than the control group and almost 
two times greater than the group of women with con-
secutive miscarriages. On the other hand, we did not 
found strong correlation between the expressions at 
the protein level of both studied genes. The observed 
difference in correlations in the group of infertile 
women might bring us closer to explain the phenome-
non of pre-clinical pregnancy loss. This phenomenon 
is on the borderline between primary infertility and 
recurrent miscarriages. There, miscarriage can occur 
shortly after implantation and because it is similar to 
menstrual bleeding it does not to arouse suspicion of 
women [53, 54]. 
Our findings may be also explained as post-tran-
scriptional expression disorder. Both HPSE and 
HB-EGF proteins are secreted out into the ECM, and 
are subject to post-translational processing. We cannot 
exclude that in some infertile women there is a defect 
that disturbs the mRNA signal sequences, controlling 
the translation or post-translational processing. Such 
a phenomenon has been postulated in the impaired 
expression of protamine in the process of spermato-
genesis [55]. Based on this assumption, no statistically 
significant differences in the level of expression of the 
studied proteins in relation to the control group can be 
explained by the action of the compensatory mechanisms 
in the endometrium in infertile women .
However, the observed correlation between 
the expression of HPSE and HB-EGF allows the 
assumption of the existence of a process by which, in 
normal human endometrium, HB-EGF expression 
stimulated by estradiol (E2) and progesterone (P4) 
coincides with the synthesis of HPSE controlled by 
E2. As a result, the HB-EGF molecule binds to the 
HS on the cell surface, enhancing its affinity to the 
EGF receptor. Then, there occurs the release of 
growth factors associated with HS oligomers which 
is catalyzed by HPSE. Despite reports indicating that 
HPSE is a factor affecting implantation and pregnancy 
development [36, 37], there are no detailed studies 
on the expression of and possible disturbances in the 
interactions between HPSE system, HS and growth 
factors involved in implantation in women with impa-
ired reproduction. This engenders another potential 
area of research because, due to their characteristics, 
HPSE and factors associated with HS should be 
considered as important parameters of endometrial 
receptivity, in both a direct and indirect way. 
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